The VICC.ORG Investigator Directory

John P. Greer, M.D.

Professor of Medicine (Hematology/Oncology), Pediatrics
Clinical Director, Hematology and Stem Cell Transplantation
VICC Member
Hematologist/Oncologist

Patient Contact Information:

Vanderbilt University Medical Center
1301 Medical Center Drive, Suite 3903
Nashville, TN 37232-5505
Appointments: 615-936-8422
Further Information: 1-877-936-8422
Fax: 615-936-1812

Healthcare Provider Contact Information:

1301 Medical Center Drive, Suite 3927 TVC
Nashville, TN 37232-5505
615-936-0381

Profile

Dr. Greer is a hematologist/oncologist who specializes in hematological malignancies and stem cell transplantation. His research interests are in the clinicopathologic description of hematologic neoplasms and in the development of therapeutic strategies to treat these disorders.

He has an expertise in T cell lymphomas and has a joint cutaneous lymphoma clinic with Dr. John Zic in dermatology. Dr. Greer's extramural activities include Chief Editor for Wintrobe's Clinical Hematology (12th edition, 2009) and member of the Lymphoma Committee for ECOG.

His research interests are in the clinicopathologic descriptions of hematologic neoplasms and in the development of therapeutic strategies to treat those disorders. Specific entities he has helped recognize include anaplastic large cell lymphoma, T-cell-rich B-cell lymphoma, and natural killer-like T-cell lymphoma/leukemia.

Education

  • Undergraduate School & Degree: Vanderbilt University B.A.
  • Medical School & Degree: Vanderbilt University School of Medicine, 1976
  • Post Graduate Training: Tulane University; Medical College of Virginia; Vanderbilt University Medical Center
  • Board & Certifications: Internal Medicine; Pediatrics
  • ABIM & Subspecialty: Hematology; Medical Oncology

Research Specialty:

Lymphoma, Leukemia, Clinical Trials, Bone Marrow Transplantation, Stem Cell Transplantation

Research Description:

My research interests are in the clinicopathologic descriptions of hematologic neoplasms and in the development of therapeutic strategies to treat these disorders. Specific entities we have helped recognize include anaplastic large cell lymphoma, T-cell-rich B-cell lymphoma, and natural killer-like T-cell lymphoma/leukemia. Since the early 1980's, we have evaluated short course, dose intensive therapy (MEGA) for intermediate to high grade lymphomas, the use of high dose cytarabine consolidation in acute nonlymphocytic leukemia, and the role of transplantation in hematologic neoplasms. We actively participate in phase I-III trials through cooperative groups (Eastern Cooperative Oncology Group and Children's Oncology Group) and with the pharmaceutical industry. We have an emphasis in studies evaluating novel agents directed at molecular pathways, immunotherapy, and transplantation.

Clinical Interest:

Non-Hodgkin's lymphoma: anaplastic large cell, peripheral T-cell, cutaneous lymphomas, T-cell-rich B-cell, natural killer-like T-cell lymphoma.
Acute and chronic leukemias.
Hodgkin's disease.
Bone marrow failure syndromes: myelodysplasia and aplastic anemia.
Stem cell transplantation.
Dose intensive therapy for hematologic malignancies.
Cooperative group trials (ECOG, CCG)

Publications:

You do not have JavaScript enabled. This site works better with JavaScript turned on.